tiprankstipranks
Trending News
More News >
Oncopeptides AB (SE:ONCO)
:ONCO
Advertisement

Oncopeptides AB (ONCO) Stock Statistics & Valuation Metrics

Compare
6 Followers

Total Valuation

Oncopeptides AB has a market cap or net worth of kr1.36B. The enterprise value is kr368.02M.
Market Capkr1.36B
Enterprise Valuekr368.02M

Share Statistics

Oncopeptides AB has 258,211,430 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding258,211,430
Owned by Insiders0.54%
Owned by Institutions

Financial Efficiency

Oncopeptides AB’s return on equity (ROE) is -5.24 and return on invested capital (ROIC) is -141.87%.
Return on Equity (ROE)-5.24
Return on Assets (ROA)-1.17
Return on Invested Capital (ROIC)-141.87%
Return on Capital Employed (ROCE)-1.47
Revenue Per Employee395.60K
Profits Per Employee-3.56M
Employee Count80
Asset Turnover0.13
Inventory Turnover0.61

Valuation Ratios

The current PE Ratio of Oncopeptides AB is ―. Oncopeptides AB’s PEG ratio is 0.07.
PE Ratio
PS Ratio8.20
PB Ratio4.78
Price to Fair Value4.78
Price to FCF-1.00
Price to Operating Cash Flow-4.22
PEG Ratio0.07

Income Statement

In the last 12 months, Oncopeptides AB had revenue of 31.65M and earned -284.61M in profits. Earnings per share was -1.71.
Revenue31.65M
Gross Profit28.98M
Operating Income-283.50M
Pretax Income-284.21M
Net Income-284.61M
EBITDA-261.81M
Earnings Per Share (EPS)-1.71

Cash Flow

In the last 12 months, operating cash flow was -324.71M and capital expenditures -357.00K, giving a free cash flow of -324.71M billion.
Operating Cash Flow-324.71M
Free Cash Flow-324.71M
Free Cash Flow per Share-1.26

Dividends & Yields

Oncopeptides AB pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.27
52-Week Price Change161.19%
50-Day Moving Average4.87
200-Day Moving Average2.48
Relative Strength Index (RSI)57.80
Average Volume (3m)4.16M

Important Dates

Oncopeptides AB upcoming earnings date is Nov 5, 2025, Before Open (Confirmed).
Last Earnings DateAug 21, 2025
Next Earnings DateNov 5, 2025
Ex-Dividend Date

Financial Position

Oncopeptides AB as a current ratio of 4.23, with Debt / Equity ratio of -185.76%
Current Ratio4.23
Quick Ratio4.14
Debt to Market Cap0.47
Net Debt to EBITDA0.14
Interest Coverage Ratio-22.40

Taxes

In the past 12 months, Oncopeptides AB has paid 398.00K in taxes.
Income Tax398.00K
Effective Tax Rate>-0.01

Enterprise Valuation

Oncopeptides AB EV to EBITDA ratio is -0.85, with an EV/FCF ratio of -0.86.
EV to Sales7.04
EV to EBITDA-0.85
EV to Free Cash Flow-0.86
EV to Operating Cash Flow-0.86

Balance Sheet

Oncopeptides AB has kr70.15M in cash and marketable securities with kr124.23M in debt, giving a net cash position of -kr54.08M billion.
Cash & Marketable Securitieskr70.15M
Total Debtkr124.23M
Net Cash-kr54.08M
Net Cash Per Share-kr0.21
Tangible Book Value Per Sharekr0.33

Margins

Gross margin is 96.58%, with operating margin of -895.78%, and net profit margin of -899.29%.
Gross Margin96.58%
Operating Margin-895.78%
Pretax Margin-898.03%
Net Profit Margin-899.29%
EBITDA Margin-827.24%
EBIT Margin-858.04%

Analyst Forecast

The average price target for Oncopeptides AB is kr5.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Targetkr5.00
Price Target Upside-5.12% Downside
Analyst ConsensusHold
Analyst Count0
Revenue Growth Forecast138.11%
EPS Growth Forecast31.65%

Scores

Smart ScoreN/A
AI Score
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis